Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL.

Clin Cancer Res. 2013 Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov 20.

2.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

3.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips GK, Atkins M.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Review.

PMID:
25323844
4.

PD-1/PD-L1 inhibitors.

Sunshine J, Taube JM.

Curr Opin Pharmacol. 2015 Aug;23:32-8. doi: 10.1016/j.coph.2015.05.011. Epub 2015 Jun 2. Review.

5.

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.

Homet Moreno B, Ribas A.

Br J Cancer. 2015 Apr 28;112(9):1421-7. doi: 10.1038/bjc.2015.124. Epub 2015 Apr 9. Review.

6.

PD-1 and PD-L1 blockade in gastrointestinal malignancies.

Lote H, Cafferkey C, Chau I.

Cancer Treat Rev. 2015 Dec;41(10):893-903. doi: 10.1016/j.ctrv.2015.09.004. Epub 2015 Sep 21. Review.

PMID:
26412280
7.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.

Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.

PMID:
25824720
8.

PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Harshman LC, Drake CG, Choueiri TK.

Cancer Immunol Res. 2014 Dec;2(12):1132-41. doi: 10.1158/2326-6066.CIR-14-0193. Review.

9.

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.

Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA.

J Oncol Pharm Pract. 2015 Dec;21(6):451-67. doi: 10.1177/1078155214538087. Epub 2014 Jun 9. Review.

PMID:
24917416
10.

Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.

Bryan LJ, Gordon LI.

Blood Rev. 2015 Jan;29(1):25-32. doi: 10.1016/j.blre.2014.09.004. Epub 2014 Sep 16. Review.

PMID:
25260226
11.

Anti-PD-1 therapy in melanoma.

Homet Moreno B, Parisi G, Robert L, Ribas A.

Semin Oncol. 2015 Jun;42(3):466-73. doi: 10.1053/j.seminoncol.2015.02.008. Epub 2015 Feb 13. Review.

PMID:
25965365
12.

Nivolumab: targeting PD-1 to bolster antitumor immunity.

Brahmer JR, Hammers H, Lipson EJ.

Future Oncol. 2015;11(9):1307-26. doi: 10.2217/fon.15.52. Epub 2015 Mar 23. Review.

13.

Immune Checkpoint Therapy in Renal Cell Carcinoma.

Lee CH, Motzer RJ.

Cancer J. 2016 Mar-Apr;22(2):92-5. doi: 10.1097/PPO.0000000000000177. Review.

PMID:
27111903
14.

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Hamid O, Carvajal RD.

Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19. Review.

PMID:
23421934
15.

PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G.

Cancer Treat Rev. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6. Review.

PMID:
25586601
16.

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Meng X, Huang Z, Teng F, Xing L, Yu J.

Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26589760
17.

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.

Chow LQ.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e280. Review.

18.

Nivolumab in renal cell carcinoma.

Michel Ortega RM, Drabkin HA.

Expert Opin Biol Ther. 2015 Jul;15(7):1049-60. doi: 10.1517/14712598.2015.1049596. Epub 2015 Jun 3. Review.

PMID:
26038957
19.

Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.

Fang XN, Fu LW.

Recent Pat Anticancer Drug Discov. 2016;11(2):141-51. Review.

PMID:
26916881
20.

Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.

PMID:
26250412

Supplemental Content

Support Center